Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ensaculin SCHEMBL29722503 | 1.00 | HTR2A (0.63) | HTR2ADRD2ADRA1AKCNH2HTR1A | |
| SCHEMBL17343106 | 0.93 | ALDH1A1 (0.58) | HTR2ADRD2ADRA1AKCNH2HTR1A | |
| SCHEMBL8805913 | 0.89 | DRD2 (0.71) | HTR2ADRD2ADRA1AHTR1A | |
| SCHEMBL6739040 | 0.88 | HTR7 (0.50) | HTR2ADRD2ADRA1AKCNH2HTR7 | |
| SCHEMBL8810740 | 0.87 | DRD2 (0.59) | HTR2ADRD2ADRA1AKCNH2 | |
| Hydrochloric Acid SCHEMBL6952251 | 0.87 | HTR7 (0.49) | HTR2ADRD2ADRA1AHTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL6740134 | 0.86 | DRD2 (0.49) | HTR2ADRD2ADRA1AHTR1AHTR7 | |
| SCHEMBL6735944 | 0.86 | DRD2 (0.48) | HTR2ADRD2ADRA1AKCNH2 | |
| SCHEMBL9144743 | 0.86 | DRD2 (0.51) | HTR2ADRD2ADRA1AKCNH2HTR1A | |
| SCHEMBL6735246 | 0.85 | DRD2 (0.47) | HTR2ADRD2ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4665318-A2 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | Native Code Bio, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2025-12-18 | — | — | US | disclosed |
| EP-4583856-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | Native Code Bio, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4547229-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | Universiteit Gent (BE) | 2025-05-07 | — | — | EP | disclosed |
| US-20250108082-A1 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | NATIVE CODE BIO, LLC | 2025-04-03 | — | — | US | disclosed |
| WO-2024173954-A2 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | NATIVE CODE BIO, LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240142458-A1 | FLUORESCENT PROBES FOR QUANTIFICATION OF FREE COPPER | Technische Universität Berlin (DE) | 2024-05-02 | — | — | US | disclosed |
| WO-2024054688-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024003363-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2024-01-04 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | HTR2A 524/4885DRD2 1115/4885ADRA1A 984/4885 |
| US-20250108082-A1 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | HMBS, P2RY13, FDPS | HTR2A 3151/4885DRD2 4096/4885ADRA1A 3887/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR2A 3184/4885DRD2 4305/4885ADRA1A 3896/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | HTR2A 269/4885DRD2 297/4885ADRA1A 1947/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | HTR2A 1221/4885DRD2 2243/4885ADRA1A 1309/4885 |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | NPC1L1, NPC1, ABCB4 | HTR2A 4186/4885DRD2 4816/4885ADRA1A 2109/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | HTR2A 273/4885DRD2 647/4885ADRA1A 1011/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR2A 406/4885DRD2 1528/4885ADRA1A 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.